• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Non-Profit MOUs

MOU No.

Purpose

Parties

FDA Lead
Center or
Office/
Contact

Effective
Date

Expiration
Date

225-03-4000B

FDA and NTEU agree to work together regarding
mandatory foreign inspection assignments.
National Treasury Employees Union (NTEU)ORA
Diana Kolaitis
(718) 662-5416

06-11-2003

expires w/contract

225-03-8004

Partnership between FDA and FDAAA on future specific undertakings that are considered beneficial for both organizations and are directly related to FDA's mission.FDA Alumni AssociationFDA/OC/OEA       Lawrence Bachorik            (301) 796-8643

03-03-2003

Indefinite

225-04-4002

FDA and BIG will work together to address issues affecting children, families, and communities within each organizations jurisdiction through educational campaigns-food safety.Blacks in Government (BIG)OC
LaJuana Caldwell
(301) 827-4450

10-22-2003

Indefinite

225-05-8000

Formalizes an agreement between FDA and the Critical Path Institute to develop collaborative activities in the areas of applied research, training and education to enhance safe and effective medical product development.C-Path InstituteCDER
ShaAvhree Buckman, M.D., Ph.D.
(301) 796-2600

05-19-2010

05-19-2015

225-09-0012Establishes a cooperative public education program between FDA, Office of External Relations, Consumer Health Information Staff and Drugs.comDrugs.comOC
Jason Brodsky
(301) 827-6251
10-13-200910-13-2012
225-09-0013Establishes a cooperative public education program between The Food and Drug Administration (FDA),Waterfront Media to provide consumers with better information and timely content concerning public health and safety topics, including emerging safety issues and product recalls.Waterfront Media

OC
Jason Brodsky
(301) 796-8234

07-18-201207-18-2017
225-09-0014Establishes the framework for collaboration between the Parties and to support their shared interest of promoting the safe use of anesthetics and sedatives in children.International Anesthesia Research Society (IARS)OC
Wendy Sanhai
(301) 796-8518
 
03-21-201003-21-2013
225-10-0006Establishes the collabloration between the FDA and the National Alliance for Hispanic Health to enhance the diversity of the pool of candidates and to promote shared interests in increasing science and public health internships opportunities for socio-economically disadvantaged students. National Alliance for Hispanic HealthOC
Mary Hitch
(301) 827-4406
01-20-201001-19-2015
225-10-0007This Memorandum of Understanding establishes the terms for collaboration between The FDA and the Association of Minority Health Professional School to enhance diversity and to promote shared interests in various science-based academic sabbaticals, fellowships and internships.The Association of Minority Health Professional School (AMHPS) OC
Mary Hitch
(301) 827-4406
01-20-2010 01-19-2015 
225-10-0021Defines the framework in which the FDA will provide publicly available content to be used in health professional informational, educational, and training programs that will be run by WebMD LLC ("WebMD") and Medscape, LLC ("Medscape"), an entity accredited by ACCME, ANCC, and the ACPT to provide continuing professional education to physicians, nurses and pharmacists, respectively. Amended to extend expiration date.Medscape, LLC and WebMDOSHI/OEA
Anna Fine
(301) 796-8471
06-07-201406-06-2019
225-11-0013Establishes a framework between The United States Food and Drug Administration (FDA) and CHDI Foundation, Inc. (CHDI) to share interests in promoting scientific progress through exchange of scientific capital in Clinical Pharmacology Training and Research.CHDI FoundationCDER
Yanig Wang
(301) 796-1624
 
08-26-201108-25-2017
225-11-0014

Establishes a cooperative public education program between The Food and Drug Administration (FDA) and The HealthCentral Network Inc. to extend the reach of FDA Consumer Health Information and provide consumers with better information and timely content concerning public health and safety topics, including emerging safety issues and product recalls.

The Health Central Network

OC
Jason Brodsky
(301) 796-8234

07-29-201107-29-2016
225-11-0017Defines the framework for collaboration between CDER and FDA and the Institute for Safe Medication Practices.  The purpose of the collaboration is to improve the safety of the American public when using CDER-regulated products. Amendment 1 to extend timeframe.Institute for Safe Medication PracticesCDER
Cynthia Fitzpatrick
(301) 796-3115
07-17-2014Indefinite
225-11-0021Establishes a strategic framework for collaboration between FDA and the Uppsala Monitoring Centre (UMC) and outlines the process for collaborative sharing of public information between the FDA and the UMC for carrying out their common goal to improve the global safety and effective use of medicinal products.Uppsala Monitoring CentreCDER
Gerald Dal Pan
(301) 796-2380
05-15-2012Indefinite
225-11-0023Establishes the cooperative efforts between FDA and NABP to enhance enforcement of applicable statutes and regulations, including the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 301et seq., and its implementing  regulations, and state statutes and regulations, to protect patients from
harm resulting from illegal domestic prescribing and dispensing of prescription drugs on the Internet.
National Association of Boards and Pharmacy

CDER
Ilisa Bernstein
(301)796-4723

08-26-201108-26-2016
225-11-0025Establishes terms to promote shared interests in various programs such as collaborative education and research.American College of Gastroenterology

CDER, Donna Griebel      (301) 796-4153

03-01-1203-01-2017
225-11-0026FDA and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) collaborate to promote scientific progress through exchange of scientific capital in a Gastroenterology Drug Development Fellowship Training and Research Program. North American Society of Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN)CDER
Donna J. Griebel, MD
(301)796-4153
 05-11-2012 05-11-2017
225-11-0029The FDA and MedStar Health collaborate to develop training programs for the FDA and potentially other government agencies, the healthcare products industry and healthcare professionals and users of medical products in the broad areas of medicine, health sciences, nursing, biomedical engineering, systems engineering, human factors, simulation and other product evaluation methods, patient safety, project management, business administration, and health policy.
 
MedStar Health

CDRH
Susan Meadows
(301) 796-6672

10-20-201110-20-2016
225-12-0006
Establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative research, public outreach, extension activities, cooperative international initiatives, and disciplinary training.
LifeScience AlleyCDRH
Michelle McMurry-Heath
(301) 796-7647
12-07-201112-07-2016
225-12-0008This document sets forth a framework for an alliance between the FDA and SOT.  It is intended to describe their combined strengths, resources, and proximity for stimulating innovation in toxicity testing, regulatory science, ethics, and education and training. Society of Toxicology (SOT)Jesse Goodman, MD
(301) 796-4880
 
 04-16-201204-16-2017
225-12-0014Defines the framework for collaboration between CDER of FDA and the Institute for Safe Medication PracticesInstitute for Safe Medication PracticesCDER
Gerald J. DalPan
(301) 796-2380
 
04-06-201204-06-2017
225-12-0016Establishes the terms for collaboration to promote shared interests between FDA and ImproveCareNowImproveCareNowCDER
Donna J. Griebel
(301) 796-4153
04-05-1204-05-2017
225-13-0021Establishes terms for collaboration to promote developing innovative health technologies that could benefit the public health.X Prize Foundation

CDRH

Murray Sheldon, MD

 (301) 796-5443

07-02-1304-31-2015
225-12-0025Collaborate and involve a consortium of various stakeholders including academic, research and clinical stakeholders, advocacy groups, industry, international partners, and others who may collaborate to advance regulatory science; and foster biomedical and biotechnology innovations, in personalized medicine, health information technology, data mining analytics, post-market safety surveillance, comparative safety and efficacy anlysis, and international harmonization to support FDA's mission.The IV2 Alliance, Inc.OC                             Walter Harris05-01-201304-30-2018
225-12-0038
Establishes the terms for collaboration to promote these shared interests education and research, and mutual exchange of training and research expertise in clinical pharmacology and translational science. 
American Society of NephrologyCDER, Patrick Archdeacon (301) 796-395209-06-2012Indefinite

225-83-3000

Defines the working arrangements between FDA and USPC in regards to the review revisions to compendial requirements for drugs.U.S. Pharmacopeial Convention, Inc. (USPC)CDER
Diane Ehrlich
(301) 443-5373

09-07-1983

Indefinite

225-84-2003

To foster and improve the sanitation and quality of shellfish in the U.S.Interstate Shellfish Sanitation Conference (ISSC)CFSAN
Donald Kraemer
(240) 402-2300

03-14-1984

Indefinite

225-93-4006

CFP and FDA agree to establish a working relationship to address issues on food safety in order to implement the recommendations adopted at Conference meetings.Conference for Food Protection (CFP)ORA
Diana Kolaitis
(718) 662-5416

08-01-1993

Indefinite

225-93-7000

Evaluating test kits for detecting animal drug residues in milkAOACCVM
Tracey Forfa
(240) 276-9006

10-22-1992

Indefinite

Girl Scouts MOU

Partnership to combat obesity in youth via education on nutrition, healthy lifestyles and physical education.Girl Scouts of the USACFSAN
Marjorie Davidson
(240) 402-1588

10-06-2004

Indefinite

225-13-0027
Collaborate on developing new methods to evaluate the toxicity of substances regulated by the FDA; improving the pathway for the review and approval of regulated substances; facilitating the FDA’s engagement with scientists from academia, government and industry on regulatory science questions that impact drug development and safety prediction; sharing information that is in the public domain and considered non-confidential; and publicly disseminating scientific knowledge to help bring safe and effective products to market.
ILSI Health and Evironmental Sciences Institute
CDER09-12-2013Indefinite
225-14-0006
Establish framework for collaboration between FDA and Washington Adventist Hospital including collaborative research, public outreach, extension activities, training, and exchange of medical professionals and staff by the two organizations.
Washington Adventist Hospital
Eileen Parish, M.D.,
Office of the Chief Scientist
(301) 796-8522
12-16-2008Indefinite
225-14-012Collaborative health professional training, outreach, and research initiatives.American Nurses AssociationTeresa Rubio                (301) 796-5113May 17, 2013Indefinite
225-14-0019Encouraging the identification, mitigation, and prevention of cybersecurity threats to medical devices.National Health Information Sharing and Analysis Center, Inc.Suzanne Schwartz, M.D., MBA (301) 796-6937August 26, 2014August 25, 2019
225-14-8000Promote awareness and understanding of gender medicine and science of sex-based differences. Karolinska Institutet

OWH

Helen J. Barr, MD

(301) 796-5713

 

 04-01-2014Indefinite
225-14-023Promoting scientific progress, furthering public policy efforts, and translating innovation and discoveries into practice in the areas of medical and biological engineering.American Institute for Medical and Biological Engineering AIMBECDRH                      Anindita Saha               (301) 796-2537 10-3-201410-2-2019

 

 

-